1 |
NCT01556191 |
Active, not recruiting |
Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR |
|
- Drug: Gefitinib
- Drug: Fulvestrant
- Drug: Erlotinib
|
Interventional |
Phase 2 |
- Intergroupe Francophone de Cancerologie Thoracique
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- progression-free survival
- Progression free survival
- toxicity of EGFR-TKI and fulvestrant
- (and 3 more...)
|
394 |
Female |
18 Years and older (Adult, Senior) |
NCT01556191 |
IFCT-1003 |
LADIE |
May 2012 |
March 2018 |
December 2018 |
March 16, 2012 |
September 20, 2017 |
|
- Annemasse - CH
Ambilly, France - Clinique de l'Europe
Amiens, France - Angers - CHU
Angers, France - (and 59 more...)
|
2 |
NCT00482118 |
Completed |
Smoky Coal Exposure, Genetic Susceptibility, and Lung Cancer in Non-Smoking Women in China |
|
|
Observational |
|
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Case-Control
- Time Perspective: Retrospective
|
- Response-gradient for PAH exposure and lung cancer risk
- Genetic polymorphisms in genes related to PAH metabolism, cell cycle control, and DNA repair associated with the risk of lung cancer
- Whether polymorphisms in genes related to PAH metabolism, cell cycle control, and DNA repair modify the PAHs-lung cancer association
|
3720 |
Female |
18 Years to 79 Years (Adult, Senior) |
NCT00482118 |
999906092 06-C-N092 |
|
March 1, 2006 |
|
|
June 4, 2007 |
April 5, 2018 |
|
- China National Environmental Monitoring Center
Beijing, China
|
3 |
NCT02725892 |
Active, not recruiting |
National Lung Cancer Registry in Men and Women Based on Diagnosis in Algeria |
- Oncology & Epidemiology & Lung Cancer
|
- Other: NIS observational stud
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- incidence of lung cancer
- incidence of newly diagnosed lung cancer
- survival
- (and 2 more...)
|
919 |
All |
Child, Adult, Senior |
NCT02725892 |
D133FR00108 |
LuCaReAl |
July 19, 2016 |
July 28, 2022 |
July 28, 2022 |
April 1, 2016 |
March 13, 2018 |
|
- CPMC
Algiers, Algeria - CHU constantine
Constantine, Algeria - CHU Oran
Oran, Algeria
|
4 |
NCT00012103 |
Completed |
Computed Tomography for Early Detection of Cancer in Women Who Are at Risk for Lung Cancer |
|
- Other: bronchoalveolar lavage
- Other: screening questionnaire administration
- Other: sputum cytology
- (and 4 more...)
|
Interventional |
Not Applicable |
- New York University School of Medicine
- National Cancer Institute (NCI)
|
Other / NIH |
- Primary Purpose: Screening
|
|
|
Female |
18 Years and older (Adult, Senior) |
NCT00012103 |
CDR0000068484 P30CA016087 NYU-9928 NCI-G01-1913 |
|
September 1999 |
December 2001 |
|
January 27, 2003 |
March 28, 2011 |
|
- NYU School of Medicine's Kaplan Comprehensive Cancer Center
New York, New York, United States
|
5 |
NCT00551733 |
Unknown † |
Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer |
|
- Drug: carboplatin
- Drug: paclitaxel
- Drug: paclitaxel poliglumex
|
Interventional |
Phase 3 |
- CTI BioPharma
- National Cancer Institute (NCI)
|
Industry |
- Allocation: Randomized
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival
- Progression-free survival
- Disease control
- (and 4 more...)
|
450 |
Female |
18 Years and older (Adult, Senior) |
NCT00551733 |
CDR0000573340 CTI-PGT-07-00400 EUDRACT-2007-004167-22 |
|
August 2007 |
|
|
October 31, 2007 |
December 16, 2010 |
|
- Scottsdale Medical Specialists
Scottsdale, Arizona, United States - Roy and Patricia Disney Family Cancer Center at Providence Saint Joseph Medical Center
Burbank, California, United States - Southwest Cancer Care - Escondido
Escondido, California, United States - (and 38 more...)
|
6 |
NCT01255059 |
Unknown † |
GWAS Research of Lung Cancer in Tianjin |
- Non-small Cell Lung Cancer
- Primary Carcinoma
|
|
Observational |
|
- Tianjin Medical University Cancer Institute and Hospital
- Tianjin Medical University Cancer Institute and Hospital
|
Other |
- Observational Model: Case Control
- Time Perspective: Retrospective
|
- Genetic variant in TP63 on locus 3q28 is associated with risk of lung adenocarcinoma among never-smoking females in Asia
|
500 |
Female |
35 Years to 80 Years (Adult, Senior) |
NCT01255059 |
TMU-CIH-GWASLC-Epi-Tianjin |
|
June 2010 |
November 2016 |
December 2016 |
December 7, 2010 |
December 22, 2015 |
|
- Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin, China
|
7 |
NCT03231111 |
Recruiting |
The Effectiveness of Using Preventive Multimedia Teaching Program in Lung Cancer Women Receiving Targeted Therapy on Skin-Related Quality of Life |
|
- Other: Preventive Multimedia Teaching Program
|
Interventional |
Not Applicable |
- National Taiwan University Hospital
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
|
60 |
Female |
20 Years to 80 Years (Adult, Senior) |
NCT03231111 |
201703118RINB |
|
July 25, 2017 |
July 1, 2018 |
December 31, 2018 |
July 27, 2017 |
July 27, 2017 |
|
- National Taiwan University Hospital
Taipei, Taiwan
|
8 |
NCT00602433 |
Completed |
Hormone Changes in Women With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Receiving Erlotinib |
- Advanced Nonsmall Cell Lung Cancer
|
|
Observational |
|
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Presence of hyperandrogenemia
- Dermatologic manifestations
- Changes in body habitus and patterns of hair loss
|
10 |
Female |
18 Years and older (Adult, Senior) |
NCT00602433 |
NU 07CC4 STU00001887 |
|
December 2007 |
August 2009 |
August 2009 |
January 28, 2008 |
April 15, 2011 |
|
- Northwestern University, Northwestern Medical Faculty Foundation
Chicago, Illinois, United States
|
9 |
NCT00932152 |
Terminated Has Results |
Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer |
- Non-small Cell Lung Cancer
- Postmenopausal Women
|
- Drug: fulvestrant (Faslodex)
- Drug: anastrozole (Arimidex)
- Drug: Bevacizumab (Avastin)
- Drug: Best supportive care
|
Interventional |
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To Evaluate the Progression-free Survival.
- To Evaluate the Time to Overall Survival, Time to Progression, and Toxicities
- To Evaluate the Levels of 17b-estradiol, VEGF, E-selectin, Thrombospondin-1 and IGF-1, and Other Biomarkers in the Plasma.
- To Evaluate Biomarkers (ERa, ERb, PR, VEGF and Aromatase Expression) in Baseline, Archival Tumor Tissue and Correlate Their Expression With Progression-free Survival, Time to Progression, and Overall Survival.
|
3 |
Female |
18 Years and older (Adult, Senior) |
NCT00932152 |
UPCI 08-131 |
|
September 2010 |
January 2013 |
January 2013 |
July 3, 2009 |
October 19, 2017 |
August 31, 2016 |
- University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania, United States
|
10 |
NCT00450281 |
Completed |
S0424 - Carcinogens in Lung Tissue From Smokers (Closed to Entry as of 7/15/07) and Non-Smokers With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer |
|
- Genetic: chromogenic in situ hybridization
- Genetic: gene expression analysis
- Genetic: mutation analysis
- (and 8 more...)
|
Observational |
|
- Southwest Oncology Group
- National Cancer Institute (NCI)
- Southwest Oncology Group
|
Other / NIH |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- DNA adduct levels
- Tumor tissue alterations
|
981 |
All |
18 Years to 120 Years (Adult, Senior) |
NCT00450281 |
CDR0000446084 S0424 U10CA032102 |
|
October 2005 |
July 2012 |
July 2012 |
March 22, 2007 |
October 26, 2015 |
|
- Providence Cancer Center
Anchorage, Alaska, United States - Arizona Cancer Center at University of Arizona Health Sciences Center
Tucson, Arizona, United States - Hembree Mercy Cancer Center at St. Edward Mercy Medical Center
Ft. Smith, Arkansas, United States - (and 402 more...)
|
11 |
NCT02666105 |
Suspended |
Exemestane in Post-Menopausal Women With NSCLC |
- Non-Small Cell Lung Cancer
|
|
Interventional |
Phase 2 |
- Masonic Cancer Center, University of Minnesota
- Masonic Cancer Center, University of Minnesota
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Disease Response
- Toxicity severity will be graded using the Common Toxicity Criteria for Adverse Events (CTCAE) version 4
- Response Duration
- (and 3 more...)
|
56 |
Female |
Child, Adult, Senior |
NCT02666105 |
2015LS095 |
|
August 2016 |
February 2019 |
February 2020 |
January 28, 2016 |
January 8, 2018 |
|
- Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota, United States
|
12 |
NCT01664754 |
Active, not recruiting |
Exemestane, Pemetrexed Disodium, and Carboplatin in Treating Post-Menopausal Women With Stage IV Non-Small Cell Lung Cancer |
- Stage IV Non-small Cell Lung Cancer
|
- Drug: exemestane
- Drug: pemetrexed disodium
- Drug: carboplatin
- (and 4 more...)
|
Interventional |
Phase 1 |
- Jonsson Comprehensive Cancer Center
- National Cancer Institute (NCI)
- Jonsson Comprehensive Cancer Center
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Tabulation, grading, and attribution of serious adverse events (SAEs) and adverse events (AEs) using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0
- Proportion achieving clinical response
- Quality of life in patients treated with pemetrexed disodium, carboplatin and exemestane
|
6 |
Female |
18 Years and older (Adult, Senior) |
NCT01664754 |
11-003323 NCI-2012-01250 |
|
September 7, 2012 |
September 30, 2018 |
September 30, 2019 |
August 14, 2012 |
September 14, 2017 |
|
- Jonsson Comprehensive Cancer Center
Los Angeles, California, United States
|
13 |
NCT00269828 |
Terminated |
A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy. |
|
- Drug: paclitaxel
- Drug: paclitaxel poliglumex
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The primary objective of this study is to compare the overall survival of female patients randomized to CT-2103 to that of female patients randomized to paclitaxel.
- Secondary objectives are to compare the progression-free survival, response rate, disease control, clinical benefit, quality of life, and the safety and tolerability of the treatment arms.
|
600 |
Female |
18 Years and older (Adult, Senior) |
NCT00269828 |
PGT305 PIONEER |
|
December 2005 |
|
December 2006 |
December 26, 2005 |
February 14, 2007 |
|
- Desert Oasis Cancer Center
Casa Grande, Arizona, United States - Arizona Hematology Oncology
Tucson, Arizona, United States - Genesis Cancer Center
Hot Springs, Arkansas, United States - (and 140 more...)
|
14 |
NCT00260871 |
Unknown † |
Genetic Epidemiological Study of Lung Cancer in Taiwan and Clinical Applications |
|
|
Observational |
|
- National Health Research Institutes, Taiwan
- National Taiwan University Hospital
- Taipei Veterans General Hospital, Taiwan
- (and 4 more...)
|
Other |
- Observational Model: Case Control
- Time Perspective: Prospective
|
|
1500 |
All |
Child, Adult, Senior |
NCT00260871 |
94LCP005 1.DOH-94-TD-G-111-025 2.DOH-94-TD-G-111-027 |
|
May 2002 |
|
|
December 2, 2005 |
July 29, 2011 |
|
- Division of Biostatistics and Bioinformatics, NHRI
Miaoli county, Taiwan
|
15 |
NCT00601146 |
Active, not recruiting Has Results |
Low-Dose Chest Computed Tomography Screening for Lung Cancer in Survivors of Hodgkin's Disease |
|
- Procedure: chest computed tomography scan
|
Observational |
|
- Dana-Farber Cancer Institute
- Brigham and Women's Hospital
- Dana-Farber Cancer Institute
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- To Prospectively Collect Data on Chest CT Screening for Patients at Increase Lung-cancer Risk After Hodgkin's Disease.
|
39 |
All |
18 Years and older (Adult, Senior) |
NCT00601146 |
06-122 |
|
November 2006 |
December 2010 |
December 2018 |
January 25, 2008 |
August 24, 2017 |
February 17, 2016 |
- Brigham and Women's Hospital
Boston, Massachusetts, United States - Dana-Farber Cancer Institute
Boston, Massachusetts, United States
|
16 |
NCT01594398 |
Completed |
Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer |
- Lung Cancer
- Non Small Cell Lung Cancer (NSCLC)
- Breast Cancer
- Estrogen Receptor Breast Cancer
|
- Drug: entinostat
- Drug: Erlotinib
- Drug: Exemestane
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Difference in pharmacokinetics of entinostat when subjects fed or fasted
- Change in laboratory values from baseline
- Change in ECG results from baseline
- (and 2 more...)
|
14 |
All |
18 Years to 90 Years (Adult, Senior) |
NCT01594398 |
SNDX-275-0110 |
ENCORE110 |
May 2012 |
April 2014 |
May 2014 |
May 9, 2012 |
June 30, 2016 |
|
- Florida Cancer Specialists
Sarasota, Florida, United States - Peggy and Charles Stephenson Cancer Center
Oklahoma City, Oklahoma, United States - Sarah Cannon Research Institute
Nashville, Tennessee, United States
|
17 |
NCT00137839 |
Active, not recruiting |
Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung |
- Adenocarcinoma
- Non-small Cell Lung Cancer
|
|
Interventional |
Phase 2 |
- Dana-Farber Cancer Institute
- Massachusetts General Hospital
- Brigham and Women's Hospital
- (and 3 more...)
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To determine how well non-small cell lung cancer cells in the body respond to Tarceva
- To determine the safety of Tarceva and what effects it has on women with adenocarcinoma of the lung
|
75 |
Female |
18 Years and older (Adult, Senior) |
NCT00137839 |
04-253 |
|
October 2004 |
December 2016 |
December 2016 |
August 30, 2005 |
August 3, 2016 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States - Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States - Dana-Farber Cancer Institute
Boston, Massachusetts, United States
|
18 |
NCT00264602 |
Active, not recruiting |
Real-Time Image Guided Lymphatic Mapping and Nodal Targeting in Lung Cancer |
|
- Drug: Near Infrared Imaging
|
Interventional |
Phase 1 |
- Dana-Farber Cancer Institute
- Brigham and Women's Hospital
- Beth Israel Deaconess Medical Center
- Dana-Farber Cancer Institute
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- To evaluate the safety and efficacy of near-infrared technology to guide therapeutic sentinel lymph node dissection in patients with lung cancer.
|
57 |
All |
18 Years and older (Adult, Senior) |
NCT00264602 |
05-219 |
|
February 18, 2009 |
September 1, 2017 |
January 2019 |
December 13, 2005 |
December 20, 2017 |
|
- Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States - Brigham and Women's Hospital
Boston, Massachusetts, United States - Dana-Farber Cancer Institute
Boston, Massachusetts, United States
|
19 |
NCT01517971 |
Recruiting |
Studying Tumor Tissue Samples From Patients With Early-Stage Non-Small Cell Lung Cancer |
|
- Other: laboratory biomarker analysis
|
Observational |
|
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
- Alliance for Clinical Trials in Oncology
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Recurrence
- Cancer specific survival
- Disease-free survival
- (and 2 more...)
|
1060 |
All |
18 Years and older (Adult, Senior) |
NCT01517971 |
CALGB-150807 CDR0000720368 |
|
January 2012 |
June 2100 |
|
January 25, 2012 |
August 8, 2017 |
|
- Brigham and Women's Hospital
Boston, Massachusetts, United States
|
20 |
NCT00312377 |
Completed Has Results |
ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer |
- Non-small Cell Lung Cancer
- Lung Cancer
|
- Drug: Docetaxel
- Drug: Vandetanib
|
Interventional |
Phase 3 |
- Genzyme, a Sanofi Company
- Sanofi
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Progression-Free Survival (PFS) in the Overall Population
- Progression-Free Survival (PFS) in the Female Population
- Overall Survival (OS) in the Overall Population
- (and 6 more...)
|
1690 |
All |
18 Years and older (Adult, Senior) |
NCT00312377 |
D4200C00032 6474IL/0032 2005-004749-32 |
ZODIAC |
May 2006 |
August 2008 |
March 2014 |
April 10, 2006 |
September 30, 2016 |
May 24, 2011 |
- Research Site
Fullerton, California, United States - Research Site
Los Angeles, California, United States - Research Site
Northridge, California, United States - (and 154 more...)
|
21 |
NCT01222572 |
Terminated Has Results |
Stereotactic Boost for Locally Advanced Non-Small Cell Lung Cancer |
- Non-small Cell Lung Cancer
- Lung Cancer
- NSCLC
|
- Radiation: Stereotactic boost
- Radiation: Conventional RT
- Drug: Etoposide
- Drug: Cisplatin
|
Interventional |
Phase 1 Phase 2 |
- Dana-Farber Cancer Institute
- Brigham and Women's Hospital
- Dana-Farber Cancer Institute
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose (MTD)
|
1 |
All |
18 Years and older (Adult, Senior) |
NCT01222572 |
10-240 |
|
December 2010 |
March 2012 |
October 2012 |
October 18, 2010 |
June 4, 2015 |
September 5, 2014 |
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
|
22 |
NCT01847209 |
Unknown † |
Percutaneous Image Guided Video-Assisted Thoracic Surgery (VATS) Resection of Lung Lesions |
|
- Procedure: Video-Assisted Thoracic Surgery (VATS) wedge resection
|
Interventional |
Phase 2 |
- Brigham and Women's Hospital
- Siemens Medical Solutions USA - CSG
- Brigham and Women's Hospital
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
25 |
All |
18 Years and older (Adult, Senior) |
NCT01847209 |
2012P001915 |
|
April 2013 |
September 2014 |
December 2015 |
May 6, 2013 |
February 24, 2015 |
|
- Brigham and Women's Hospital
Boston, Massachusetts, United States
|
23 |
NCT00899782 |
Active, not recruiting |
Collection and Storage of Blood and Tissue Samples From Patients Who Are Undergoing Surgery For Lung Cancer |
- Lung Carcinoma
- Lung Neoplasm
- Malignant Lung Neoplasm
|
- Other: cytology specimen collection procedure
|
Observational |
|
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
- Alliance for Clinical Trials in Oncology
|
Other / NIH |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Collection and storage of frozen tissue samples for molecular analysisor resection of lung cancer
- Collection and storage of frozen blood samples for the assessment of somatic mutations and levels of circulating markersto assess levels of circulating markers
|
500 |
All |
18 Years and older (Adult, Senior) |
NCT00899782 |
CALGB-140202 CDR0000271323 U10CA031946 U10CA180821 |
|
July 2004 |
January 2100 |
|
May 12, 2009 |
August 8, 2017 |
|
- Tunnell Cancer Center at Beebe Medical Center
Lewes, Delaware, United States - CCOP - Christiana Care Health Services
Newark, Delaware, United States - Union Hospital of Cecil County
Elkton, Maryland, United States - (and 16 more...)
|
24 |
NCT02429843 |
Recruiting |
A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer |
|
|
Interventional |
Phase 1 |
- University of Alabama at Birmingham
- Tracon Pharmaceuticals Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of patients with a change in medical management
- Measurement of tumor response
- Progression-free survival
- (and 5 more...)
|
18 |
All |
19 Years and older (Adult, Senior) |
NCT02429843 |
F150128005 (UAB 1504) |
|
September 27, 2016 |
September 2019 |
September 2020 |
April 29, 2015 |
January 9, 2018 |
|
- UAB Comprehensive Cancer Center
Birmingham, Alabama, United States
|
25 |
NCT02502695 |
Recruiting |
A Study to Optimize Care for Lung Cancer Patients Undergoing Video-Assisted Thoracoscopic Surgery (VATS) |
|
- Other: VATS-associated best practices
|
Observational |
|
- Dana-Farber Cancer Institute
- Ethicon Endo-Surgery
- Dana-Farber Cancer Institute
|
Other / Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Readmissions rates within 30 days of the patient's surgery date
- Incidence of post-operative complications within 30 days of the patient's surgery date
- Total inpatient cost
- Difference in readmission rates between the two cohorts
|
400 |
All |
18 Years and older (Adult, Senior) |
NCT02502695 |
15-193 |
|
June 2015 |
December 2018 |
December 2019 |
July 20, 2015 |
February 16, 2017 |
|
- Providence Saint John's Health Center
Santa Monica, California, United States - Georgetown University Medical Center
Washington, District of Columbia, United States - WellStar Medical Group
Austell, Georgia, United States - (and 3 more...)
|
26 |
NCT02336061 |
Terminated |
Evaluation of Gender Differences on the Psychosocial and Economic Impact in Patients With Advanced Non-small Cell Lung Cancer |
- Non-small Cell Lung Cancer
|
- Behavioral: Evaluation of gender differences on the psychosocial and economic impact.
|
Observational |
|
- Asociación para la Investigación del Cáncer de Pulmón en Mujeres
- Pivotal S.L.
- Asociación para la Investigación del Cáncer de Pulmón en Mujeres
|
Other / Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Psychosocial impact (Test Family APGAR, Partner Test and adapted Duke-UNC-11 Scale)
- Economic impact (employment status, working hours, income range, public assistance, family support ...)
- Influence of treatment (reatment received, treatment received, tumour ssessment, Medical history, including history of smoking, ECOG performance status, associated medical conditions and prior treatments administered (surgery, adjuvant treatment).
- Psychosocial and economic impact on the primary caregiver (Zarit Caregiver Burden Questionnaire and Test assessing the economic impact)
|
344 |
All |
18 Years and older (Adult, Senior) |
NCT02336061 |
ICA-QUI-2014-01 |
IMPULSO |
February 3, 2015 |
November 30, 2017 |
November 30, 2017 |
January 12, 2015 |
December 15, 2017 |
|
- Hospital German Trias i Pujol
Badalona, Barcelona, Spain - Hospital Provincial de Castellón
Castellón de la Plana, Castellón, Spain - Hospital Universitario Son Espases
Palma de Mallorca, Islas Baleares, Spain - (and 15 more...)
|
27 |
NCT02950337 |
Recruiting |
Stereotactic Body Radiation Therapy for Un-biopsied Early- Stage Non Small Cell Lung Cancer |
- Non Small Cell Lung Cancer
|
- Radiation: Group 1: Peripherally Located Tumors
- Radiation: Group 2: Peripherally Located Chest Wall Adjacent Tumors
- Radiation: Group 3: Centrally Located Tumors
|
Interventional |
Phase 2 |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Toxicity Evaluation
- Disease Specific Outcomes
|
41 |
All |
18 Years and older (Adult, Senior) |
NCT02950337 |
208111 208111102115 |
|
December 2015 |
December 2020 |
December 2022 |
November 1, 2016 |
December 8, 2017 |
|
- Loyola University Medical Center
Maywood, Illinois, United States
|
28 |
NCT01885754 |
Recruiting |
Characterization of Peripheral Muscle Function in Patients With Non-small-cell Lung Cancer |
- Non-Small-cell Lung Cancer
|
|
Observational |
|
- Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Maximal quadriceps strength
- Exercise capacity
|
56 |
All |
40 Years to 80 Years (Adult, Senior) |
NCT01885754 |
20878 |
|
February 2013 |
July 2017 |
October 2017 |
June 25, 2013 |
January 6, 2017 |
|
- Institut universitaire de cardiologie et de pneumologie de Québec
Québec, Quebec, Canada
|
29 |
NCT01684696 |
Not yet recruiting |
Virtual Intervention for Lung Cancer |
|
- Behavioral: Virtual experience
- Behavioral: Videos
|
Interventional |
Not Applicable |
- University of California, San Francisco
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Supportive Care
|
- Patient-clinician communication scores
- Perceived lung cancer stigma
- Lung Cancer symptoms
- (and 2 more...)
|
50 |
All |
21 Years and older (Adult, Senior) |
NCT01684696 |
12-09184 (pC ID): 237290 |
VILC |
August 2016 |
August 2017 |
September 2017 |
September 13, 2012 |
June 17, 2016 |
|
- UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States
|
30 |
NCT03234179 |
Not yet recruiting |
A Prognosis and Predicting Genetic Study of Lung Cancer |
- Lung Cancer
- Genetic Predisposition to Disease
|
|
Observational |
|
- National Taiwan University Hospital
|
Other |
- Observational Model: Family-Based
- Time Perspective: Prospective
|
- Genetic information of lung cancer patients
|
500 |
All |
20 Years and older (Adult, Senior) |
NCT03234179 |
201705110RIND |
|
August 1, 2017 |
August 1, 2020 |
August 1, 2037 |
July 31, 2017 |
August 1, 2017 |
|
|
31 |
NCT01147562 |
Recruiting |
Biomarker Discovery and Validation in Lung Cancer |
|
- Procedure: Collection of biospecimen
|
Interventional |
Not Applicable |
- Dr. Guy Berchem
- Integrated Biobank of Luxembourg
- Centre Hospitalier du Luxembourg
- Public Research Centre Health, Luxembourg
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
|
- Discover and validate molecular biomarkers for lung cancer
|
150 |
All |
18 Years and older (Adult, Senior) |
NCT01147562 |
IBBL0001 |
LCS |
October 2009 |
July 2017 |
October 2020 |
June 22, 2010 |
January 19, 2017 |
|
- Centre Hospitalier de Luxembourg (CHL)
Luxembourg, Luxembourg - Clinique Sainte Thérèse (Zithaklinik)
Luxembourg, Luxembourg
|
32 |
NCT01928836 |
Completed |
Risk Stratification of Patients Using the Lung Cancer Biomarker Panel in China |
|
|
Observational |
|
- Bai Chunxue
- Shanghai Zhongshan Hospital
- Peking Union Medical College Hospital
- (and 5 more...)
|
Other |
- Observational Model: Case Control
- Time Perspective: Prospective
|
- Incidence rate of lung cancer
|
764 |
All |
40 Years to 75 Years (Adult, Senior) |
NCT01928836 |
CAALC-001-LCBP |
LCBP |
October 2012 |
January 2014 |
January 2015 |
August 27, 2013 |
May 27, 2015 |
|
- Peking Union Medical College Hospital
Beijing, China - Third Military Medical University
Chongqing, China - First Affiliated Hospital of Zhejiang University
Hangzhou, China - (and 3 more...)
|
33 |
NCT02853006 |
Recruiting |
Study on Fluids Associated to Lung Cancer |
|
- Biological: Blood and respiratory fluids sampling
- Procedure: Biopsy
- Procedure: Excised tissues
|
Interventional |
Not Applicable |
- University Hospital, Grenoble
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Quantification of : DNA
- Quantification of : RNA
|
200 |
All |
18 Years and older (Adult, Senior) |
NCT02853006 |
38RC15.099 |
ECTOPIC/MUTAS |
June 2015 |
June 2019 |
June 2019 |
August 2, 2016 |
August 2, 2016 |
|
- UniversityHospitalGrenoble
La Tronche, France
|
34 |
NCT02024113 |
Completed |
LC-NMR Study Biomarkers to Detect Lung Cancer |
|
- Other: Venous blood sample
|
Observational |
|
- Hasselt University
- Ziekenhuis Oost-Limburg
- Algemeen Ziekenhuis Vesalius
- (and 2 more...)
|
Other |
- Observational Model: Case Control
- Time Perspective: Prospective
|
- Metabolic phenotype of lung cancer
- Overall survival
- Progression-free survival
- (and 2 more...)
|
646 |
All |
18 Years and older (Adult, Senior) |
NCT02024113 |
12/081U |
|
February 2013 |
December 2014 |
January 2015 |
December 31, 2013 |
February 10, 2015 |
|
- Ziekenhuis Oost-Limburg
Genk, Limburg, Belgium - Hasselt University
Hasselt, Limburg, Belgium
|
35 |
NCT01414595 |
Completed |
Study of Tissue Samples From Patients With Non-Small Cell Lung Cancer |
|
- Genetic: DNA analysis
- Genetic: DNA methylation analysis
- Genetic: RNA analysis
- (and 4 more...)
|
Observational |
|
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
- Alliance for Clinical Trials in Oncology
|
Other / NIH |
- Observational Model: Case-Only
- Time Perspective: Retrospective
|
- Identification and characterization of SNVs in primary adenocarcinoma of the lung or squamous cell carcinoma of the lung
- Identification and characterization of structural variations in the genomes of NSCLC
- Identification and characterization of other genomic alterations including, but not limited to, gene expression profiling and methylation
|
248 |
All |
18 Years and older (Adult, Senior) |
NCT01414595 |
CALGB-151107 CDR0000706375 |
|
March 2012 |
February 2017 |
|
August 11, 2011 |
June 27, 2017 |
|
- Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center
Los Angeles, California, United States - Tunnell Cancer Center at Beebe Medical Center
Lewes, Delaware, United States - CCOP - Christiana Care Health Services
Newark, Delaware, United States - (and 8 more...)
|
36 |
NCT01255150 |
Completed |
Frequency of EGFR Mutations in Latinos/Hispanics With Non-Small Cell Lung Cancer |
- Non-Small-Cell Lung Carcinoma
|
|
Observational |
|
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Ecologic or Community
- Time Perspective: Cross-Sectional
|
- Frequency of EGFR mutations in Hispanic/Latinos with nonsmall cell lung cancer according to gender and smoking status
- Association between the frequency of EGFR mutations and the percentage of American Indian ancestry, as defined by genetic ancestry analysis, in Hispanic/Latinos with non-small cell lung cancer
|
15 |
All |
2 Years to 100 Years (Child, Adult, Senior) |
NCT01255150 |
110044 11-C-0044 |
|
December 1, 2010 |
|
April 29, 2015 |
December 7, 2010 |
April 6, 2018 |
|
- Denver Health Medical Center
Denver, Colorado, United States - National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States - Kettering Health Network
Kettering, Ohio, United States - (and 9 more...)
|
37 |
NCT00003566 |
Completed |
Thoracoscopy in Patients With Stage IIIA Non-Small Cell Lung Cancer |
|
- Procedure: videothoracoscopy
|
Interventional |
Not Applicable |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
- Alliance for Clinical Trials in Oncology
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
75 |
All |
18 Years and older (Adult, Senior) |
NCT00003566 |
CALGB-39803 U10CA031946 CLB-39803 CDR0000066632 |
|
September 1998 |
March 2006 |
March 2006 |
January 27, 2003 |
July 14, 2016 |
|
- Northeast Alabama Regional Medical Center
Anniston, Alabama, United States - Rebecca and John Moores UCSD Cancer Center
La Jolla, California, United States - Veterans Affairs Medical Center - San Diego
San Diego, California, United States - (and 69 more...)
|
38 |
NCT01966003 |
Completed Has Results |
Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer |
- Non-small Cell Lung Cancer Metastatic
|
- Drug: Carboplatin
- Drug: Paclitaxel
- Drug: ABP 215
- Drug: Bevacizumab
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Percentage of Participants With an Objective Response
- Duration of Response
- Progression-free Survival
- (and 3 more...)
|
642 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT01966003 |
20120265 2013-000738-36 |
|
November 11, 2013 |
July 23, 2015 |
July 23, 2015 |
October 21, 2013 |
October 19, 2017 |
October 19, 2017 |
- Research Site
Bismarck, North Dakota, United States - Research Site
Fremantle, Western Australia, Australia - Research Site
Veliko Tarnovo, Veliko Turnovo, Bulgaria - Research Site
Ruse, Bulgaria
|
39 |
NCT00341835 |
Recruiting |
Genetic Epidemiology of Lung Cancer |
|
|
Observational |
|
- National Human Genome Research Institute (NHGRI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Family-Based
- Time Perspective: Prospective
|
- Detection of gene(s) contributing to lung cancer risk
- Determine whether there are gene-gene or gene-environment interactions contributing to lung cancer risk
|
9999 |
All |
5 Years and older (Child, Adult, Senior) |
NCT00341835 |
999903288 03-HG-N288 |
|
August 26, 2003 |
|
|
June 21, 2006 |
March 2, 2018 |
|
- National Human Genome Research Institute (NHGRI), 9000 Rockville Pike
Bethesda, Maryland, United States
|
40 |
NCT00970645 |
Terminated |
Study Comparing EBUS & EUS to Mediastinoscopy in Staging and Detection of Lung Cancer |
- Non Small Cell Lung Cancer
|
- Procedure: Mediastinoscopy/thoracoscopy
- Procedure: EBUS/EUS
|
Interventional |
Not Applicable |
- Mayo Clinic
- Medical University of South Carolina
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Develop an integrated staging technique to detect early metastases in lung cancer which should affect patient outcomes more accurately than conventional staging techniques.
|
2 |
All |
21 Years and older (Adult, Senior) |
NCT00970645 |
09-002240 DOD protocol A-12345.8 |
|
February 2010 |
March 2011 |
March 2011 |
September 2, 2009 |
July 18, 2011 |
|
- Mayo Clinic
Jacksonville, Florida, United States - Mayo Clinic
Rochester, Minnesota, United States - Medical University of South Carolina
Charleston, South Carolina, United States
|
41 |
NCT00418886 |
Active, not recruiting Has Results |
Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients |
- Non Small Cell Lung Cancer
- Lung Cancer
|
- Drug: Vandetanib
- Drug: Pemetrexed
|
Interventional |
Phase 3 |
- Genzyme, a Sanofi Company
- Sanofi
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Progression-Free Survival (PFS) in the Overall Population
- Progression-Free Survival (PFS) in the Female Population
- Overall Survival (OS)
- (and 7 more...)
|
698 |
All |
18 Years and older (Adult, Senior) |
NCT00418886 |
D4200C00036 EUDRACT No. 2006-003695-35 |
ZEAL |
January 2007 |
September 2008 |
December 2019 |
January 5, 2007 |
March 8, 2017 |
March 26, 2012 |
- Research Site
Casa Grande, Arizona, United States - Research Site
Chandler, Arizona, United States - Research Site
Farmington, Connecticut, United States - (and 107 more...)
|
42 |
NCT01139619 |
Completed |
A Retrospective Study to Investigate the Current Situation of Biopsy Testing in Swedish Inoperable Non Small Cell Lung Cancer (NSCLC) Patients |
- Non Small Cell Lung Cancer
|
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Describe complications connected to biopsy and bronchoscopy in the investigated lung cancer population.
- Describe time to diagnosis for patients diagnosed by transthoracic biopsy compared to patients diagnosed by bronchoscopy.
- Describe difference in clinical outcome for patients diagnosed by histopathology compared to patients diagnosed by cytology alone, one year after diagnosis.
|
136 |
All |
Child, Adult, Senior |
NCT01139619 |
NIS-OSE-DUM-2010/1 |
MAPSY |
October 2010 |
January 2013 |
January 2013 |
June 8, 2010 |
February 25, 2013 |
|
- Research Site
Gavle, Sweden - Research Site
Linkoping, Sweden - Research Site
Lulea, Sweden
|
43 |
NCT00339859 |
Recruiting |
DNA Repair, p53 and Apoptosis Phenotypes in Lung Cancer |
|
|
Observational |
|
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Case-Control
- Time Perspective: Cross-Sectional
|
|
6000 |
All |
18 Years to 90 Years (Adult, Senior) |
NCT00339859 |
999998027 OH98-C-N027 |
|
June 2, 1995 |
|
|
June 21, 2006 |
January 26, 2018 |
|
- University of Maryland, Baltimore
Baltimore, Maryland, United States - Johns Hopkins University
Baltimore, Maryland, United States - Sinai Hospital of Baltimore
Baltimore, Maryland, United States
|
44 |
NCT01141946 |
Completed |
Pleural Ultrasonography in Lung Cancer |
|
- Procedure: thoracic ultrasound
- Procedure: pleural aspiration
|
Observational |
|
- Centre hospitalier de l'Université de Montréal (CHUM)
- Fonds de la Recherche en Santé du Québec
- Centre de Recherche du Centre Hospitalier de l'Université de Montréal
- Society of University Surgeons
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- The improvement in pre-operative staging with the addition of pre-operative pleural ultrasonography for malignant pleural effusion.
- The ability of pre-operative diaphragmatic ultrasound to predict post-operative morbidity following pulmonary surgery.
|
46 |
All |
18 Years and older (Adult, Senior) |
NCT01141946 |
CE 10.046 |
CT0018 |
June 2010 |
September 2010 |
October 2010 |
June 11, 2010 |
July 17, 2012 |
|
- Centre Hospitalier de l'Université de Montréal
Montreal, Quebec, Canada
|
45 |
NCT00317200 |
Completed |
A Study of Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer |
|
- Drug: Paclitaxel
- Drug: Bevacizumab
|
Interventional |
Phase 2 |
- Hoosier Cancer Research Network
- Genentech, Inc.
- Walther Cancer Institute
- Hoosier Cancer Research Network
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To determine progression free survival(PFS) of this regimen in patients with chemosensitive relapsed small cell lung cancer (SCLC).
- To determine the response rate of the combination of paclitaxel and bevacizumab with chemosensitive SCLC.
- To determine the toxicity of the combination of paclitaxel and bevacizumab in patients with SCLC.
- (and 2 more...)
|
34 |
All |
18 Years and older (Adult, Senior) |
NCT00317200 |
HOG LUN05-99 |
|
April 2006 |
November 2007 |
November 2007 |
April 24, 2006 |
May 2, 2011 |
|
- Highlands Oncology Group
Springdale, Arkansas, United States - Medical & Surgical Specialists, LLC
Galesburg, Illinois, United States - Cancer Care Center of Southern Indiana
Bloomington, Indiana, United States - (and 14 more...)
|
46 |
NCT01248806 |
Active, not recruiting |
Continuous Observation of Smoking Subject |
- Subjects at High Risk of Lung Cancer Due to Smoking
|
- Radiation: Low dose CT scan
|
Observational |
|
- European Institute of Oncology
- Associazione Italiana per la Ricerca sul Cancro
- European Institute of Oncology
|
Other |
- Observational Model: Case-Only
- Time Perspective: Retrospective
|
- To determine the prevalence of malignant pulmonary disease at the first CT examination
- To assess the radiological detection of disease during the 10 year follow-up
- To determine the overall resectability of detected malignant tumours
|
5203 |
All |
50 Years and older (Adult, Senior) |
NCT01248806 |
IEO S39/100 |
COSMOS |
October 2004 |
January 2017 |
December 2017 |
November 25, 2010 |
August 10, 2016 |
|
- European Institute of Oncology
Milan, Italy
|
47 |
NCT00840749 |
Terminated |
Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer |
- Non-small Cell Lung Cancer
|
- Radiation: CyberKnife Stereotactic Radiotherapy
- Procedure: Surgery
|
Interventional |
Phase 3 |
- Accuray Incorporated
- M.D. Anderson Cancer Center
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival
- Compare disease specific survival, progression free survival at the treated primary tumor site, grade 3 and above acute and/or chronic toxicities,and evaluate predictive value of pre and post treatment PET scan in clinical outcome
|
36 |
All |
18 Years and older (Adult, Senior) |
NCT00840749 |
STARS |
STARS |
December 2008 |
March 2013 |
March 2013 |
February 10, 2009 |
April 8, 2013 |
|
- Community Regional Medical Center
Fresno, California, United States - Penrose Cancer Center
Colorado Springs, Colorado, United States - Denver CyberKnife
Lone Tree, Colorado, United States - (and 16 more...)
|
48 |
NCT00809237 |
Unknown † |
Hydroxychloroquine and Gefitinib to Treat Lung Cancer |
- Non-small Cell Lung Cancer
|
- Drug: Gefitinib, Hydroxychloroquine
|
Interventional |
Phase 1 Phase 2 |
- National University Hospital, Singapore
- Massachusetts General Hospital
- AstraZeneca
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- For the phase I lead in study: To identify the tolerability, the dose limiting toxicity (DLT) and the general safety profile of HCQ and gefitinib when used in combination.
- For the phase II study: To determine the response rates to HCQ and Gefitinib.
- For the phase I lead in study: To determine the PK (pharmacokinetic) parameters of HCQ plus gefitinib.
- For the phase II study: To determine the time to progression for patients treated with HCQ and Gefitinib.
|
71 |
All |
21 Years and older (Adult, Senior) |
NCT00809237 |
NS 01/03/08 2008/00196 |
|
November 2008 |
November 2014 |
November 2014 |
December 17, 2008 |
December 10, 2013 |
|
- National University Hospital
Singapore, Singapore
|
49 |
NCT00003692 |
Completed |
Video-Assisted Surgery in Treating Patients With Non-small Cell Lung Cancer |
|
- Procedure: therapeutic thoracoscopy
- Procedure: video-assisted surgery
|
Interventional |
Phase 2 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
- Eastern Cooperative Oncology Group
- Alliance for Clinical Trials in Oncology
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- survival
- failure-free survival
|
128 |
All |
Child, Adult, Senior |
NCT00003692 |
CALGB-39802 U10CA031946 CLB-39802 E-C39802 CDR0000066795 |
|
December 1998 |
March 2006 |
March 2006 |
April 9, 2004 |
July 20, 2016 |
|
- Veterans Affairs Medical Center - Birmingham
Birmingham, Alabama, United States - CCOP - Scottsdale Oncology Program
Scottsdale, Arizona, United States - University of California San Diego Cancer Center
La Jolla, California, United States - (and 112 more...)
|
50 |
NCT01221675 |
Completed |
TF2- Small Cell Lung Cancer Radio Immunotherapy |
- Small Cell Lung Cancer
- CEA-expressing Non Small Cell Lung Carcinoma (NSCLC)
|
- Drug: Antibody TF2
- Radiation: IMP-288-Lutetium
- Radiation: IMP-288-Indium
|
Interventional |
Phase 1 Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Primary endpoint of study plan I: To determine the optimal TF2 protein dose for pretargeting IMP-288.
- Primary endpoint of study plan II • the maximum tolerated dose (MTD) for the TF2-pretargeted 177Lu-IMP-288 under optimal pretargeting conditions.
|
18 |
All |
18 Years and older (Adult, Senior) |
NCT01221675 |
BRD 08/9-O |
|
June 2011 |
April 2016 |
April 2016 |
October 15, 2010 |
August 31, 2016 |
|
- CHU d'Angers
Angers, France - CHU
Brest, France - Centre Jean Perrin
Clermont Ferrand, France - (and 3 more...)
|